TP53 and mantle cell lymphoma: In MCL, in contrast to the CLL, primary resistance to Ibrutinib is more common, occurring in 32%, which could stem from the fact that MCL has a higher rate of high-risk mutations such as mutations in the ATM and TP53 gene in 44% and 27%, respectively [24] [67].